PPAR and immune system - what do we know?

被引:96
|
作者
Zhang, X [1 ]
Young, HA [1 ]
机构
[1] NCI, Expt Immunol Lab, Ctr Canc Res, Frederick, MD 21702 USA
关键词
fatty acids; NK cells; nuclear hormone receptor; Th1/Th2; differentiation; transcription;
D O I
10.1016/S1567-5769(02)00057-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear steroid receptor superfamily. Originally, the receptors were identified as critical controllers for several key enzymes that catalyze the oxidation of fatty acids. PPARs consist of three members: PPAR-alpha, PPAR-beta/delta, and PPAR-gamma. Among them, PPAR-gamma is essential for controlling thermogenesis and adipocyte differentiation. The ligands for PPAR-gamma include 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2))-a metabolite from the prostaglandin synthesis pathway, and "glitazones "-drugs utilized in the treatment of patients with diabetes. The precursors for prostaglandins are fatty acids consumed from diet and these precursors have long been postulated to have a regulatory role in immune functions. Emerging evidence indicates that PPAR-gamma and its ligands are indeed important for the modulation of immune and inflammatory reactions. In this review, we will spotlight the molecular mechanisms of receptor/ligand function and how they may regulate immune and inflammatory reactions. We also propose that PPAR-gamma and its endogenous ligands are participating factors for Type 1 /Type 2 T and NK cell differentiation and development. Deciphering the mechanism of action of PPAR-gamma and its ligands may lead to a new therapeutic regiment for treatment of diseases involving dysfunction of the immune system. (C) 2002 Elsevier Science B.V All rights reserved.
引用
收藏
页码:1029 / 1044
页数:16
相关论文
共 50 条
  • [1] The Mosquito Immune System and the Life of Dengue Virus: What We Know and Do Not Know
    Mukherjee, Debica
    Das, Sandeepan
    Begum, Feroza
    Mal, Sweety
    Ray, Upasana
    PATHOGENS, 2019, 8 (02):
  • [2] What we know and what we do not know
    McDonald, JC
    RADIATION PROTECTION DOSIMETRY, 2005, 113 (02) : 127 - 128
  • [3] We do not know what we do not know
    Spaeth, GL
    OPHTHALMIC SURGERY AND LASERS, 1999, 30 (05): : 337 - 340
  • [4] Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
    Perazella, Mark A.
    Shirali, Anushree C.
    KIDNEY INTERNATIONAL, 2020, 97 (01) : 62 - 74
  • [5] We know what they think, but do we know what they do?
    Callingham, M
    Baker, T
    INTERNATIONAL JOURNAL OF MARKET RESEARCH, 2002, 44 (03) : 299 - 335
  • [6] What do we know? What do we need to know?
    Milena J. Henzlova
    W. Lane Duvall
    Journal of Nuclear Cardiology, 2017, 24 : 252 - 254
  • [7] What do we know? What do we need to know?
    Henzlova, Milena J.
    Duvall, W. Lane
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 252 - 254
  • [8] Genetic platforms: Do we do what we know? or do we know what we do?
    Bernet, Laia
    Pla, Maria Jesus
    Janez, Noelia Martinez
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2021, 34 (02): : 100 - 110
  • [9] Quasicrystals: What do we know? What do we want to know? What can we know?
    Steurer, Walter
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : 1 - 11
  • [10] Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know?
    Amauri Dalla Corte
    Carolina F. M. de Souza
    Maurício Anés
    Roberto Giugliani
    Child's Nervous System, 2017, 33 : 1073 - 1080